Clinical Trial Search

Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Selpercatinib — 898; 1170; 732; 952 nanogram per milliliter (ng/mL) — p=0.3601

Primary: Number of Participants Reporting Serious Adverse Events (SAEs) Throughout the Study — 0; 0; 0; 0 Participants

Primary: Number of Solicited Adverse Events — 1; 0; 0; 0 events

Primary: Part A: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) Assessed Using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events…

Primary: Maximum Observed Concentration (Cmax) of Ritlecitinib: MR Capsules vs Oral Solution Under Fasted Condition — 671.6; 145.1; 84.96 Nanogram per milliliter (ng/mL)

Primary: Part 1: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0 Participants

Primary: Reinforcing Effects (Pre-Alcohol Dose Consumption) — 0.005; .01; 0.007; 0.005 Units on a Theoretical Scale

Primary: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC) for a Single Dose Bimekizumab (BKZ) — 1223; 1255 days*micrograms/milliliter (days*ug/mL)

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 1; 2; 1; 2 Participants

Primary: Change in Subject-Rated Outcome - VAS Drug Liking — 3; 53.33; 58.89; 38.78 score on a scale

Primary: Number of Participants With Dose-limiting Toxicities(DLTs) — 1; 4 Participants

Primary: Compare Exposure to Diclofenac — 141.5; 166.1; 202.3 ng*hr/mL

Primary: Part 1: Number of Participants With Adverse Events That Are Related to Treatment With ISIS 814907 — 3; 0; 5; 4 Participants

Primary: Safety - Serious Adverse Event — 0; 0; 0 SAEs

Primary: The Incidence of DLTs in the First 56 Days (8 Weeks) of Dosing to Determine Tolerable Phase 2/3 Dose of Canakinumab, Spartalizumab, Nab-paclitaxel and Gemcitabine in…